A phase 3b safety study of fixed-dose durvalumab plus tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A. Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Sonpavde, Guru; Peters, Solange; Nordquist, Luke T.; Kato, Terufumi; Miranda, Paulo Andre; Wang, Qin; Socinski, Mark A.

authors

Publication Date

  • February 20, 2018

webpage

published in

category

volume

  • 36

issue

  • 6